The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known by brand names Ozempic and Wegovy, has the ability to counter metabolic dysfunction-associated steatohepatitis, or MASH, liver disease and some of its risk factors.

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.

A new study published in the New England Journal of Medicine reveals that medications widely used for diabetes and obesity may offer significant benefits for patients with liver disease, adding to the growing list of potential applications for these popular drugs.